Production & Sales - Marketing & Sales

World’s largest pharmaceutical firm selects ValGenesis to standardize corporate validation process enterprise-level

ValGenesis has announced that one of the world's largest, top rated life science companies has chosen to implement its 100% paperless Validation Lifecycle Management System (VLMS) across all its global sites to manage the corporate validation lifecycle process.

Sobi acquires Synagis US rights from AstraZeneca

Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of US rights of Synagis (palivizumab) from AstraZeneca in a deal valued at around $1.6bn.

Circassia to buy US, China marketing rights to AIT’s AirNOvent

Circassia Pharmaceuticals has agreed to acquire the exclusive commercialization rights of AIT Therapeutics’ ventilator compatible nitric oxide product AirNOvent in the US and China.

Acrotech to buy seven hematology/oncology products from Spectrum

Aurobindo Pharma’s subsidiary Acrotech Biopharma has agreed to acquire seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals in a deal valued at around $300m.

Luye Pharma grants AstraZeneca exclusive rights to promote Xuezhikang Capsules in mainland China

Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma’s Xuezhikang Capsules in mainland China.

Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada

Puma Biotechnology has entered into an exclusive license agreement with Knight Therapeutics that grants Knight the exclusive right to commercialize NERLYNX (neratinib) in Canada.

Eusa Pharma acquires iMCD treatment Sylvant for $115m

Biopharmaceutical firm Eusa Pharma has purchased worldwide rights of Sylvant (siltuximab) from Janssen Sciences Ireland for $115m.

Nuvo Pharmaceuticals completes acquisition of revenue-generating products from Aralez

Canadian healthcare company Nuvo Pharmaceuticals has completed the previously announced acquisition of a portfolio of more than 20 revenue-generating products from Aralez Pharmaceuticals.

Opiant and Sanofi sign licensing deal for drinabant

Opiant Pharmaceuticals has signed a licensing agreement with Sanofi for the development and commercialisation of drinabant across the globe for the treatment of acute cannabinoid overdose (ACO).